Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Sep 21, 2014; 20(35): 12581-12587
Published online Sep 21, 2014. doi: 10.3748/wjg.v20.i35.12581
Published online Sep 21, 2014. doi: 10.3748/wjg.v20.i35.12581
Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma
Masayoshi Yada, Akihide Masumoto, Kenta Motomura, Hirotaka Tajiri, Yusuke Morita, Hideo Suzuki, Takeshi Senju, Toshimasa Koyanagi, Department of Hepatology, Iizuka Hospital, Iizuka, Fukuoka 820-8505, Japan
Author contributions: Yada M, Masumoto A, Motomura K, Tajiri H, Morita Y, Suzuki H, Senju T and Koyanagi T designed and performed the research; Yada M analyzed data; Yada M and Masumoto A wrote the paper.
Correspondence to: Akihide Masumoto, MD, PhD, Department of Hepatology, Iizuka Hospital, 3-83 Yoshio-machi, Iizuka, Fukuoka 820-8505, Japan. amasumotoh1@aih-net.com
Telephone: +81-948-22-3800 Fax: +81-948-29-5744
Received: February 19, 2014
Revised: April 10, 2014
Accepted: June 21, 2014
Published online: September 21, 2014
Processing time: 212 Days and 1.9 Hours
Revised: April 10, 2014
Accepted: June 21, 2014
Published online: September 21, 2014
Processing time: 212 Days and 1.9 Hours
Core Tip
Core tip: Clinical factors influencing the efficacy of sorafenib for treating patients with advanced hepatocellular carcinoma (HCC) were evaluated in this study. As only the size of the largest tumor correlated significantly with overall survival, analyses were focused on factors affecting time to progression (TTP). Sorafenib was more effective for treating patients with extrahepatic compared to intrahepatic advanced HCC. The occurrence of hand-foot syndrome as an adverse event significantly correlated with increased TTP and may therefore be a useful indicator for adjusting the dose of sorafenib to improve its effectiveness and the health-related quality of life of patients with advanced HCC.